On Wednesday, Jefferies made an adjustment to the price target for UnitedHealth Group (NYSE:UNH), lowering it slightly from $643.00 to $647.00, while still endorsing the stock with a Buy rating. The firm's analysis suggests caution is warranted due to higher than anticipated spending in Part D, which was approximately 10% above their expectations.
The commentary from UnitedHealth's third-quarter financial results indicated potential challenges for other insurance payers as well. The firm highlights that the guidance for 2025 from UnitedHealth suggests an earnings per share (EPS) increase of $2.25, which represents an 8% year-over-year growth. This projection is based on a starting point of $4.00, the midpoint of the Long Range Plan (LRP), adjusted for the $1.75 headwinds that appeared in the third quarter and are expected to continue into the next year.
Despite these headwinds, Jefferies maintains a positive outlook on UnitedHealth Group. The firm expects that at the upcoming Investor Day, UnitedHealth's OptumHealth segment is likely to show growth starting in the range of approximately 650,000, which supports their decision to maintain a Buy rating on the stock.
The price adjustment reflects a nuanced view of the challenges and growth prospects for UnitedHealth, factoring in recent developments and forward-looking expectations. The maintained Buy rating indicates the firm's continued confidence in the company's performance despite the slight decrease in the price target.
In other recent news, UnitedHealth Group has faced some significant changes and challenges. Deutsche Bank has adjusted its price target for UnitedHealth, reducing it to $595 from the previous $595, while maintaining a Buy rating on the stock. This decision was taken following UnitedHealth's third-quarter results and comments on the company's earnings per share (EPS) outlook for 2025. The company's initial guidance for approximately $30 in EPS was roughly 4% below the consensus estimate of about $31.25.
Furthermore, UnitedHealth's guidance suggests an increase in the medical loss ratio (MLR) of 25-40 basis points for 2025, which is contrary to investor expectations of MLR improvement. This rise in MLR is attributed to a variety of factors, including increased hospital coding intensity and a persistent gap between Medicaid patient acuity and state reimbursement rates.
In addition to these developments, UnitedHealth confirmed its full-year earnings outlook during its third quarter 2024 earnings call, regardless of challenges such as Medicare rate cuts and Medicaid member redeterminations. The company reported robust growth, serving over 2 million new consumers in commercial offerings and processing 1.6 billion prescriptions through Optum Rx. The third quarter revenues reached $101 billion, marking a 9% increase, while UnitedHealthcare added over 2.4 million members.
Lastly, the company projects the upper end for 2025 earnings to be around $30 per share. These recent developments highlight UnitedHealth's continued focus on value-based care and the utilization of AI to enhance care efficiency. While the company faces challenges from Medicare rate cuts and Medicaid member redeterminations, it remains optimistic about growth potential in Medicare Advantage and value-based care models.
InvestingPro Insights
To complement Jefferies' analysis of UnitedHealth Group (NYSE:UNH), InvestingPro data offers additional perspective on the company's financial health and market position. UnitedHealth's revenue for the last twelve months as of Q3 2024 stands at $393.9 billion, with a robust revenue growth of 9.42% over the same period. This aligns with the firm's status as a prominent player in the Healthcare Providers & Services industry, as noted in one of the InvestingPro Tips.
The company's financial stability is further underscored by its dividend performance. An InvestingPro Tip highlights that UnitedHealth has raised its dividend for 14 consecutive years, demonstrating a commitment to shareholder returns even in challenging market conditions. This is particularly relevant given Jefferies' cautious stance on higher-than-expected Part D spending.
Despite the headwinds mentioned in the article, UnitedHealth's P/E Ratio (Adjusted) for the last twelve months as of Q3 2024 is 25.0, suggesting that investors are still willing to pay a premium for the company's earnings. This valuation could be supported by another InvestingPro Tip indicating that the stock generally trades with low price volatility, which may be attractive to investors seeking stability in the healthcare sector.
For readers interested in a more comprehensive analysis, InvestingPro offers 11 additional tips on UnitedHealth Group, providing a broader perspective on the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.